LifeSci Capital analyst Cory Jubinville, PhD maintained a Buy rating on Crinetics Pharmaceuticals (CRNX – Research Report) today and set a price target of $82.00.
Cory Jubinville, PhD’s rating is based on Crinetics Pharmaceuticals’ promising developments and strategic initiatives. The company has demonstrated significant progress in its clinical trials, particularly with its lead asset, paltusotine, which has shown positive results in treating uncontrolled acromegaly and carcinoid syndrome. Additionally, Crinetics is advancing its first-in-class ACTH-receptor antagonist, atumelnant, for conditions like congenital adrenal hyperplasia and Cushing’s Disease.
Looking forward, Crinetics is well-positioned for potential market expansion with plans to seek approval for paltusotine in Europe, supported by a positive opinion from the EMA’s Committee for Orphan Medicinal Products. The company’s strong cash position of approximately $1.4 billion allows it to aggressively pursue multiple programs, including the initiation of four new INDs in 2025. These strategic moves, combined with the company’s focus on pre-commercialization efforts, underpin the Buy rating as Crinetics prepares for potential market launches and further clinical advancements.
In another report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $100.00 price target.